ReviewJHEP reports : innovation in hepatology2025
Non-invasive assessment of portal hypertension: Liver stiffness and beyond.
Review in JHEP reports : innovation in hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Ultrasound and point shear-wave elastography assessment for predicting esophageal varices in schistosomiasis-associated non-cirrhotic portal hypertension.Abdominal radiology (New York) · 2026Article
- Noninvasive test patterns across vascular and parenchymal liver diseases.Wiener klinische Wochenschrift · 2026Article
- Changes in SSM Assessed via 100 Hz-VCTE Are Associated With Acute HVPG-Response to i.v. Propranolol: A European Multicentre Study.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Advances in Precise Assessment of Portal Pressure in Porto-sinusoidal Vascular Disease.Journal of clinical and translational hepatology · 2026Review
- Review
- Recent Advances in the Diagnosis and Management of Clinically Significant Portal Hypertension in Liver Cirrhosis: A Clinical Review.Biomedicines · 2026Review
- Indocyanine Green Clearance Correlates With Biomarkers Reflecting Key Disease-Driving Mechanisms in Advanced Chronic Liver Disease and Predicts Acute-on-Chronic Liver Failure and Death.Alimentary pharmacology & therapeutics · 2026Article
- Biomarkers of Extracellular Matrix Remodelling Are Linked to Severity and Outcome of Advanced Chronic Liver Disease.Alimentary pharmacology & therapeutics · 2026Article
- Article
- Endohepatology: Evolving Indications, Challenges, Unmet Needs and Opportunities.Gastro hep advances · 2026Review
- Predicting Clinically Significant Portal Hypertension in MASLD Using Routine Ultrasound and Clinical Data: A Retrospective Cohort Study.BioMed research international · 2026Article
- Predicting decompensation risk in compensated HBV cirrhosis: Eternal sunshine for a spotless mind?: Editorial on "Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis".Clinical and molecular hepatology · 2026Article
- Article
- Never change a winning team-liver stiffness measurement and platelet count as key surrogates for clinically significant portal hypertension.Hepatobiliary surgery and nutrition · 2025Article
- Disease-modifying effect of efruxifermin in compensated cirrhosis due to MASH: To miss the forest for the tree(s).JHEP reports : innovation in hepatology · 2025Article
- Advances in portal hypertension management: Evolution of the Baveno guidelines.World journal of gastroenterology · 2025Review
- Assessment of liver stiffness measurement-related markers in predicting liver-related events in viral cirrhosis with clinically significant portal hypertension.World journal of hepatology · 2025Article
- Liver Involvement in Celiac Disease and Immune-Mediated Diseases of the Small Bowel.Liver international : official journal of the International Association for the Study of the Liver · 2025Review
- Harnessing the therapeutic value of Tanshinone IIA: a breakthrough therapy in cardiovascular diseases.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Portal hypertension (PH) leads to life-threatening clinical manifestations such as bleeding from gastro-oesophageal varices, ascites and its complications, and portosystemic encephalopathy. It can develop because of advanced chronic liver disease (ACLD) or due to rarer causes such as vascular liver disease. Reference standard methods to assess PH in ACLD include the measurement of hepatic venous pressure gradient and endoscopy, which have limitations due to their high resource utilisation and invasiveness. Non-invasive tests (NITs) have entered clinical practice and allow invasive procedures to be reserved for patients with indeterminate findings on NITs or for specific clinical questions. In this review, we present an update on the role of NITs, and in particular ultrasound elastography, to diagnose PH in ACLD and vascular liver disease, and to stratify the risk of liver-related events. We also provide insights into the open research questions and design of studies in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.